EyePoint, Inc. announced that its Phase 3 clinical trial for DURAVYU, a treatment for wet age-related macular degeneration, failed to meet the primary endpoint. Following this announcement, EyePoint's stock price dropped over 66%, causing significant losses for investors. A law firm, Kessler Topaz Meltzer & Check, LLP, is investigating potential securities law violations and is offering legal assistance to affected investors. This development raises concerns about the future prospects of EyePoint's treatment and its financial stability.
Dogecoin (DOGE) has been fully integrated onto the Solana blockchain through Wormhole's Native Token Transfers (NTT) framework and the Sunrise liquidity gateway. This integration, covering DOGE's entire $35 billion circulating supply, allows DOGE to ...
Bittensor (TAO) surged 8.33% to $264.83, nearing its $300 target after a 25% gain over five sessions. The rally is driven by new trading access on Raydium, increased activity from the parody token Buttensor, protocol upgrades, and rising derivatives ...
Bitcoin remains stuck below $80,000 following stronger-than-expected US payroll data that revived fears of a Federal Reserve rate hike. Despite a sharp drop and liquidations, market expectations for a Fed hike remain steady, with the upcoming CPI rep...
Samuel Smith, an experienced dividend stock analyst, recently sold his position in Ares Capital Corporation after initially buying the dip earlier this summer. He had previously rated the company as a buy, considering it a strong business development...
XRP experienced an extraordinary 10,535% liquidation imbalance within an hour as its price dropped to $1.38 during a Labor Day liquidity dip. This was caused by a cascade of forced margin calls, with long positions being liquidated far more than shor...
